Clinical Trials
10
Active:0
Completed:7
Trial Phases
3 Phases
Phase 2:6
Phase 4:3
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Phase 2
6 (60.0%)Phase 4
3 (30.0%)Not Applicable
1 (10.0%)A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD
Phase 4
- Conditions
- Age-Related Macular Degeneration (AMD)
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2007-01-15
- Lead Sponsor
- Eyetech Pharmaceuticals
- Target Recruit Count
- 1000
- Registration Number
- NCT00354445
- Locations
- 🇺🇸
Retina Research Institute of Texas, LLC, Abilene, Texas, United States
A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.
Phase 2
Completed
- Conditions
- Age-Related Macular Degeneration
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2006-05-04
- Lead Sponsor
- Eyetech Pharmaceuticals
- Target Recruit Count
- 540
- Registration Number
- NCT00321997
A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)
Phase 4
Terminated
- Conditions
- Macular Degeneration
- First Posted Date
- 2006-04-10
- Last Posted Date
- 2007-01-15
- Lead Sponsor
- Eyetech Pharmaceuticals
- Target Recruit Count
- 262
- Registration Number
- NCT00312351
- Locations
- 🇺🇸
Charlotte Eye, Ear, Nose and Throat Associates, P.A., Charlotte, North Carolina, United States
Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)
Phase 2
Completed
- Conditions
- Age-Related Macular Degeneration
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2006-05-03
- Lead Sponsor
- Eyetech Pharmaceuticals
- Target Recruit Count
- 125
- Registration Number
- NCT00215670
Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)
Phase 4
Terminated
- Conditions
- Age-Related Macular Degeneration
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2007-01-15
- Lead Sponsor
- Eyetech Pharmaceuticals
- Target Recruit Count
- 360
- Registration Number
- NCT00134667
- Locations
- 🇺🇸
Retina Centers, P.C., Northwest Location, Tucson, Arizona, United States
- Prev
- 1
- 2
- Next
News
No news found